$191 Million is the total value of Stonepine Capital Management, LLC's 26 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $14,226,000 | -13.3% | 2,694,295 | -21.2% | 7.44% | -16.1% |
| OVID | Sell | OVID THERAPEUTICS INC | $7,820,000 | -21.7% | 2,000,000 | -19.5% | 4.09% | -24.2% |
| AFMD | Sell | AFFIMED NV | $7,225,000 | -11.3% | 850,000 | -17.5% | 3.78% | -14.2% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $6,174,000 | -22.7% | 762,183 | -47.4% | 3.23% | -25.1% |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $4,792,000 | -55.8% | 200,000 | -52.6% | 2.51% | -57.2% |
| ISEE | Sell | IVERIC BIO INC | $3,265,000 | -39.6% | 517,445 | -40.9% | 1.71% | -41.6% |
| EYPT | Sell | EYEPOINT PHARMACEUTICALS INC | $2,732,000 | -18.3% | 303,851 | -7.7% | 1.43% | -20.9% |
| XGN | Sell | EXAGEN INC | $2,541,000 | -24.0% | 169,542 | -11.2% | 1.33% | -26.4% |
| DMAC | Sell | DIAMEDICA THERAPEUTICS INC | $1,869,000 | -80.0% | 419,942 | -59.0% | 0.98% | -80.7% |
| CFRX | Sell | CONTRAFECT CORP | $296,000 | -77.1% | 67,208 | -75.0% | 0.16% | -77.8% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $125,000 | -87.2% | 46,886 | -85.2% | 0.06% | -87.6% |
| AGTC | Sell | APPLIED GENETIC TECHNOLOGIES | $4,000 | -99.6% | 1,000 | -99.4% | 0.00% | -99.6% |
| ONCS | Exit | ONCOSEC MEDICAL INC | $0 | – | -94,783 | -100.0% | -0.24% | – |
| BWAY | Exit | BRAINSWAY LTDsponsored ads | $0 | – | -55,181 | -100.0% | -0.27% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -10,000 | -100.0% | -0.42% | – |
| APVO | Exit | APTEVO THERAPEUTICS INC | $0 | – | -38,593 | -100.0% | -0.64% | – |
| AYTU | Exit | AYTU BIOPHARMA INC | $0 | – | -362,910 | -100.0% | -1.49% | – |
| PLXP | Exit | PLX PHARMA INC | $0 | – | -506,274 | -100.0% | -2.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.